Life Sciences High-Throughput Screening Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences High-Throughput Screening Platforms
1.1 - About Life Sciences High-Throughput Screening Platforms sector
Companies in the Life Sciences High-Throughput Screening Platforms category build integrated automation and analytics solutions for drug discovery teams, enabling rapid, reproducible testing of large compound libraries against biological targets. For analysts seeking strategic buyers in high-throughput screening, these vendors combine robotics, assay instrumentation, and informatics to increase throughput, reduce cycle times, and improve data quality across biopharma, biotech, CROs, and academic centers.
Their platforms typically combine robotic liquid handling and acoustic dispensing with microplate readers and high-content imaging to run biochemical, cell-based, and phenotypic assays at scale. Vendors provide assay development toolkits, compound management and sample tracking, and tight LIMS/ELN integration through secure data pipelines. They also deliver cheminformatics and HTS analytics for hit calling, SAR exploration, and dose–response curve fitting, plus cloud or on‑prem workflow orchestration with scheduling and instrument integration.
They serve biopharma R&D organizations, emerging biotech discovery teams, and contract research labs, as well as academic screening cores. Buyers achieve faster hit identification, lower per‑assay costs, higher reproducibility and data integrity, and scalable throughput that compresses cycle times from library preparation through triage, enabling better portfolio decisions and more efficient lead optimization.
2. Buyers in the Life Sciences High-Throughput Screening Platforms sector
2.1 Top strategic acquirers of Life Sciences High-Throughput Screening Platforms companies
Inflammatix
- Description: Provider of host-response molecular diagnostics that leverage machine learning and immune system mRNA profiling to give emergency clinicians rapid, accurate insight into bacterial or viral infections and illness severity, enabling earlier, more confident treatment decisions.
- Key Products:
- TriVerity Test: Rapid whole-blood assay that analyzes host mRNA signatures with machine-learning algorithms to deliver three scores indicating likelihood of bacterial infection, viral infection and risk of severe illness within minutes, guiding rule-in/rule-out decisions in the ED
- TriVerity Instrument & Cartridge: Compact point-of-care device using single-use cartridges to run the TriVerity assay at bedside, enabling precision decision-making when time, space and certainty are limited
- Host Response Diagnostic Platform: Proprietary bioinformatics and AI framework that ‘reads’ immune system signatures to create highly accurate, actionable tests for acute infections and sepsis, outperforming traditional pathogen-targeted methods.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences High-Throughput Screening Platforms sector
M&A buyer group 1: Cheminformatics for Drug Discovery
Certara
- Type: N/A
- Employees: ●●●●●
- Description: Provider of integrated drug-development solutions that apply AI-enabled cheminformatics, biosimulation, and regulatory expertise to guide biopharma partners from discovery through market access, replacing guesswork with data-driven insights and accelerating delivery of life-changing medicines.
- Key Products:
- Early Phase Clinical Development solutions: Provide expert support at every stage, from candidate selection through Phase 1, ensuring informed decision-making and streamlined early development activities
- Pharmacometrics services: Experienced team quantifies drug-patient interactions and optimizes development and regulatory choices, guiding evidence-based dose selection and program decisions
- Quantitative Systems Pharmacology (QSP) consulting: Enhances drug development by integrating computational modeling with experimental data to predict outcomes and refine therapeutic strategies
- Simcyp PBPK modeling consulting: Global experts apply physiologically-based pharmacokinetic modeling across all development stages to anticipate exposure, support trial design, and address regulatory questions.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences High-Throughput Screening Platforms sector
3.1 - Buyout funds in the Life Sciences High-Throughput Screening Platforms sector
2.2 - Strategic buyer groups for Life Sciences High-Throughput Screening Platforms sector
4 - Top valuation comps for Life Sciences High-Throughput Screening Platforms companies
4.2 - Public trading comparable groups for Life Sciences High-Throughput Screening Platforms sector
Valuation benchmark group 1: Clinical and Molecular Diagnostics Companies
Labcorp
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of comprehensive clinical laboratory and drug development services, harnessing science for human good with a wide range of diagnostic tests, specialty testing services, and research support globally.
- Key Products:
- Diagnostic Testing: Wide range of diagnostic tests for various conditions
- Specialty Testing: Advanced gene-based and esoteric testing
- Drug Development Services: Comprehensive services for drug development and clinical trials
- Health Screenings: Wellness, pediatric, COVID-19 antibody testing
- Labcorp OnDemand: At-home test kits and monitoring solutions